Chapter 13 of 25
What you will learn
- Understand hysterectomy, ovary removal and lymph-node assessment.
- Discuss minimally invasive surgery and selected ovarian preservation.
- Prepare for recovery and recognize complications.
Removing the uterus and related structures
A total hysterectomy removes the uterus and cervix. Bilateral salpingo-oophorectomy removes both fallopian tubes and ovaries and is commonly performed with it. Removal of ovaries before natural menopause causes surgical menopause. Hysterectomy permanently prevents carrying a pregnancy, even if ovaries are retained.
The operation for endometrial cancer is not automatically a radical hysterectomy of the type used for some cervical cancers. Additional procedures depend on histology and spread. Selected aggressive histologies may require assessment or removal of the omentum, a fatty apron inside the abdomen, because microscopic disease can occur there.
Surgical approach
Laparoscopic or robotic minimally invasive surgery is commonly preferred for appropriate uterus-confined disease because it can reduce wound problems and recovery time compared with a large incision. Open surgery may be necessary for extensive disease, a large uterus or technical and medical reasons. The surgeon should explain why a particular approach is recommended.
Cancer tissue should be removed in a way that avoids spilling or fragmenting it inappropriately. Uncontained morcellation is not an acceptable shortcut for a known uterine malignancy. The endometrial evidence should not be confused with the different evidence concerning minimally invasive radical hysterectomy for cervical cancer.
Lymph nodes
Sentinel-node mapping identifies the first draining nodes using a tracer and removes them for detailed examination. A validated mapping algorithm includes assessment of suspicious nodes and a plan if mapping fails. It can provide staging information while reducing the morbidity of removing many nodes in suitable patients.
Systematic lymphadenectomy may be needed in selected circumstances, but removing every node is not routinely beneficial for every low-risk cancer. Node surgery can cause lymphoedema, fluid collections, nerve or vessel injury. Ask how the results would change treatment and why the proposed extent is appropriate.
Ovarian preservation and special situations
Ovarian preservation may be considered in carefully selected premenopausal patients with low-risk disease, after discussing hereditary risk, ovarian involvement and future health. It is not suitable for every histology or genetic situation. Preserving ovaries preserves hormone production and potentially eggs, but does not preserve the ability to carry a pregnancy after hysterectomy.
If surgery is medically unsafe, definitive radiotherapy, often including brachytherapy, may offer a curative option in selected localized cancers. Hormonal approaches may be appropriate in other carefully assessed situations. Inability to undergo surgery does not mean there are no treatments.
Recovery and warning signs
| Common recovery issue | Helpful approach |
|---|---|
| Pain and fatigue | Use the prescribed plan and increase activity gradually |
| Constipation | Discuss fluids, movement and suitable medicines |
| Clot risk | Follow mobility and prescribed prevention instructions |
| Vaginal healing | Follow individualized advice about lifting, intercourse and insertion |
Seek urgent care for sudden breathlessness, chest pain, a swollen painful leg, heavy bleeding, fever, worsening abdominal pain or inability to pass urine. Do not wait for the routine follow-up visit if these occur. Recovery restrictions vary with the operation and complications; obtain written instructions rather than relying on a universal timetable.
Questions and take-home messages
Ask which organs will be removed, whether sentinel mapping is planned, what happens if spread is found and when final pathology will be discussed. The postoperative appointment should address both healing and the cancer plan, including menopause, sexual wellbeing and any additional treatment.
Related chapters
- Fertility-Preserving Treatment
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- Berek et al. FIGO staging of endometrial cancer, 2023
- NCI: Endometrial Cancer Treatment, patient version
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy